An Observational, Longitudinal Study to Describe the Outcome, and Outcome Predictors, of Patients With Primary Membranous Nephropathy, and the Nephrotic Syndrome Treated With Rituximab, or Other Monoclonal Antibodies
Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY
This is an observational study intended to track the course of the primary membranous nephropathy disease in real-world clinical practice. The study will primarily assess the long-term outcomes of patients with primary membranous nephropathy in the context of advances in treatment options.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adults (≥18 years old) on the day of signing informed consent.
• Diagnosis of primary membranous nephropathy
• Nephrotic syndrome (proteinuria \>3.5 g/24 hours)
• Written informed consent to the use of recorded data for research purposes.
Locations
Other Locations
Italy
ASST HPG23 - Unità di Nefrologia
ACTIVE_NOT_RECRUITING
Bergamo
Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò
RECRUITING
Ranica
Contact Information
Primary
Matias Trillini, MD
matias.trillini@marionegri.it
+3903545351
Backup
Piero L Ruggenenti, MD
pruggenenti@asst-pg23.it
Time Frame
Start Date: 2024-11-29
Estimated Completion Date: 2054-06
Participants
Target number of participants: 500
Related Therapeutic Areas
Sponsors
Leads: Mario Negri Institute for Pharmacological Research